In our recent Experts Knowledge Share, world-renowned experts discussed case studies, reviewed the latest data and shared their views. 

Guest expert Prof. Fred Saad joined GU CONNECT members Assoc. Prof Tanya Dorff, Prof. Gerhardt Attard, and Prof. Neeraj Agarwal, along with participants from around the world, to discuss incorporating PARP inhibitors into prostate cancer clinical practice

GU CONNECT invites you to watch the video replay, download the accompanying slides, and take the e-learning using the blue button below the video to claim your CME credit.

 


Incorporating PARP inhibitors into prostate cancer clinical practice.

Video Chapters

Chapter 1  00:00     Scene-setting - Prof. Fred Saad

Chapter 2  05:23     Use of PARP inhibitors beyond the first-line setting in mCRPC - Prof. Fred Saad and Prof. Gerhardt Attard

Chapter 3  39:24     Use of PARP inhibitors in the first-line setting in mCRPC - Assoc. Prof. Tanya Dorff and Prof. Neeraj Agarwal

Chapter 4  1:09:50  Questions and panel discussion

Chapter 5  1:14:06   Future perspectives and summary - Prof. Fred Saad

 

Clinical Takeaways

 

  • PARP inhibitors are an important part of the treatment strategy for mCRPC patients

  • mCRPC patients who harbour HRR mutations benefit from PARPi monotherapy following progression on prior novel hormonal agents

  • Treatment with PARP inhibitors plus novel hormonal agents can provide combination benefits in mCRPC patients with or without HRR mutations

  • The future treatment landscape for prostate cancer patients will likely include the earlier introduction of PARPi's and treatment beyond patients with HRR/DRR mutations

President of the National Cancer Institute of Canada G‐U Group, the Canadian Urologic Oncology Group and GU Global ▪ Member of ten editorial boards and serves as a reviewer for more than 30 urology and oncology journals. Published over 300 scientific articles and book chapters and has collaborated on over 800 scientific abstracts presented at scientific meetings around the world. ▪ Co‐editor of several books, including the first two editions of Understanding Prostate Cancer, which sold over 150,000 copies. ▪ Main research interests include molecular prognostic markers in prostate cancer and new treatments for advanced prostate cancer. He is currently coordinating more than 40 clinical and basic research projects in urologic oncology.

Prof. Fred Saad has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA/Novartis, Abbvie, Astellas, AstraZeneca, Amgen, Bayer, Janssen, Merck, Myovant, Pfizer, Sonofi and Tolmar. 

 

 

Following a residency at Mt. Sinai Hospital in New York City, Dr Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently heads the Genitourinary group within the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center. In addition to being a devoted clinician and translational researcher, Dr Dorff has authored more than 45 peer reviewed articles as well as 35 review articles/commentaries. Dr Dorff serves as an associate editor for Clinical Genitourinary Cancer and Seminars in Urologic Oncology. She has lectured on prostate and bladder cancer treatment nationally and internationally and has presented her research at national meetings. Current research interests include the effects of fasting on chemotherapy side effects and cancer control and immunotherapy for prostate cancer. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.

Assoc. Prof. Tanya Dorff has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Astellas, Exelixis, Janssen and SeaGen.

Prof. Attard is a Cancer Research UK Clinician Scientist and Team Leader at The Institute of Cancer Research and an Honorary Medical Oncology Consultant at the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration-resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 100 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. Prof. Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. Prof. Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.

Prof. Gerhardt Attard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, AstraZeneca, Bayer,  Janssen, Novartis and Pfizer. 

Neeraj Agarwal, MD, is a Professor in the Division of Oncology, Department of Medicine, at the University of Utah School of Medicine. He is the Senior Director for Clinical Research Innovation at Huntsman Cancer Institute, and the HCI Presidential Endowed Chair of Cancer Research. He also serves as the Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, Salt Lake City, Utah, and directs the Center of Investigational Therapeutics and co-leads the “Experimental Therapeutic Program” at HCI. As a specialist in adult hematology and oncology, Dr Agarwal cares for patients with all types of cancer and specializes in genitourinary malignancies (cancers of the prostate, kidney, bladder and testes). Dr Agarwal is a member of several professional societies, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the Southwest Oncology Group (SWOG). After receiving his MD degree from All India Institute of Medical Sciences in New Delhi, India, Dr Agarwal completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa. He then completed a hematology-oncology fellowship at HCI and the University of Utah School of Medicine. Dr Agarwal has received several awards and grants and has authored more than 300 peer-reviewed articles and book chapters. He has given talks at several prestigious regional and national forums and serves as a panel member for the NCCN guideline-committees for bladder and kidney cancer. Dr Agarwal also serves as the overall study chair and/or steering committee member of multiple national and international clinical trials in GU cancers. Dr Agarwal has the prestigious honor of being chosen as one of the five young investigators of the Southwest Oncology Group in 2009. He has been appointed as the leader of early therapeutics of the SWOG Genitourinary Cancer Committee in 2010. Dr Agarwal is also the recipient of the prestigious 2009-2010 William D. Odell Young Investigator award from the University of Utah’s, Department of Medicine, and the 2014 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.

Prof. Neeraj Agarwal has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Arnivas, Astellas, AstraZeneca, Bavarian Nordic , Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon.

Programme summary
TAKE THE E-LEARNING
Share this programme
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca
Accreditation
EACCME
This course has been accredited by EACCME® for 1 ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

video Video
Oncology 
ER+ metastatic breast cancer: Elacestrant and beyond

Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer

Experts
Prof. Maria Vittoria Dieci
Endorsed by
GRASP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology.
podcast Podcast

Episode

3

of 3

episode
Oncology 
Ovarian Cancer: Pre-analytical phase challenges and biomarker testing

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
micro-learning Micro learning

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
micro-learning Micro learning

Module

1

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Advanced HCC: Treatment options for patients ineligible for IO

Explore treatment options, adverse event management and next steps in this interactive patient case

Experts
Prof. Sammy Saab
Endorsed by
Blue Faery Digestive Cancers Europe 5th anniversary
Global Liver Institute
  • clock 15 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from Bayer.
podcast Podcast

Episode

2

of 3

episode
Oncology 
Lung Cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 2 of a 3-part video podcast series

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.